Loading…
A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,649 other S bills in the 118th — cohort avg 33d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2024 · first_quarter · Health Issues
Issues related to Valley fever; H.R. 6227/S.3220 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; H.R. 6731/S.3464, the FORWARD Act.
Client expense: Not reported · Firm income: $30,000
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Health Issues
Issues related to Valley fever; H.R. 6227/S.3220 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; H.R. 6731/S.3464, the FORWARD Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Health Issues
H.R.6227 - Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023; S.3220 - A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis; legislation related to Valley fever.
Client expense: Not reported · Firm income: Not reported
| Republican |
| OK |